查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1983803

感染疾病治疗市场：2026-2032年全球市场预测（依药物类别、给药途径、适应症、最终用户和分销管道划分）

Infectious Disease Therapeutics Market by Drug Class, Route Of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，感染疾病治疗市场价值将达到 1,268 亿美元，到 2026 年将成长至 1,325.9 亿美元，到 2032 年将达到 1,831.3 亿美元，复合年增长率为 5.39%。

主要市场统计数据
基准年 2025 1268亿美元
预计年份：2026年 1325.9亿美元
预测年份 2032 1831.3亿美元
复合年增长率 (%) 5.39%

为感染疾病治疗市场制定简洁的策略框架，以增强相关人员对临床创新、监管趋势和营运重点的理解。

目前感染疾病治疗正处于关键转折点，这主要得益于分子生物学的进步、疫苗研发进程的加速以及日益复杂的全球供应链格局。本导言为研究、生产、临床实践和政策领域的相关人员提供了一个策略背景，重点阐述了科学创新与监管调整如何整合并影响短期决策。此外，本导言也确立了贯穿整个报告的分析观点：一种将治疗方法、给药途径和最终用户实际情况与营运限制和商业性机会联繫起来的综合观点。

技术进步、监管现代化和不断变化的临床需求如何重新定义感染疾病治疗的开发路径和商业化策略。

感染疾病治疗领域正经历变革性的转变，这得益于技术突破、新的监管模式以及不断变化的临床需求。基因疗法和生物製药疗法日趋成熟，单株抗体和细胞激素调变器不再只是治疗工具，而是综合治疗方法中不可或缺的一部分。同时，能够实现快速设计、迭代改进和适应性生产的疫苗技术平台正在重塑针对不同病原体的预防策略。这些技术进步伴随着数位技术和诊断技术的进步，使得早期检测和更具针对性的治疗方法成为可能，从而改变了临床路径和支付方的考量。

对 2025 年关税趋势将如何重塑治疗领域的供应链策略、采购决策和生产在地化进行全面分析。

2025年美国关税政策发展的累积影响将重塑整个感染疾病治疗生态系统的供应链经济、采购行为和策略采购决策。关税变化正直接影响活性成分、生物製药以及商业生产和研发营运所需的试剂的成本。由此带来的单位经济效益压力迫使製造商重新评估供应商多元化、库存持有策略以及近岸外包方案，以降低进口相关成本波动带来的风险。

透过提供将治疗领域、给药途径、临床适应症、分销管道和最终用户趋势联繫起来的综合细分观点，我们提供了确定优先事项所需的必要资讯。

细分市场分析揭示了产品、剂量和临床用途的差异，这些差异从根本上改变了药物的研发和商业化策略。从药物类别（抗生素、抗真菌药物、抗病毒药物、生物製药和疫苗）的角度来看，每一类药物都面临独特的临床和生产方面的考量。抗生素在各种亚类中都保持着重要性，包括Aminoglycosides、β-内酰胺类、Fluoroquinolones、大环内酯类和四环霉素，每种抗生素具有不同的抗药性动态和合理用药需求，这些都会影响临床指南和采购偏好。抗真菌药物，包括Azole、Echinocandins和Polyenes，面临独特的诊断和剂量复杂性，这影响它们在医院处方集和门诊治疗中的应用。抗病毒药物，例如整合酶抑制剂、神经氨酸酶抑制剂、核苷类似物和蛋白酶抑制剂，具有治疗特异性和抗药性，因此需要联合用药策略和用药依从性干预措施。

美洲、欧洲、中东、非洲和亚太地区的监管多样性、製造能力和医疗保健系统优先事项如何决定医疗服务取得和策略重点。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的监管时间表、生产策略和患者用药途径都产生了重大影响。在美洲，法规环境差异显着，既有核准流程完善、高度集中的体系，也有可能延误跨境用药的分散式司法管辖结构。这种多样性要求企业制定差异化的打入市场策略、策略性的价格谈判以及确保持续供应的紧急时应对计画。在欧洲、中东和非洲（EMEA）地区，相关人员必须应对复杂的监管方式、报销框架和公共卫生优先事项。在此背景下，联合采购机制和区域疾病负担在部署曲线和公开竞标中发挥着至关重要的作用。

关键竞争模式揭示了推动感染疾病治疗领域成功的科学差异化、製造策略和伙伴关係模式。

感染疾病治疗领域主要企业之间的竞争格局是由科学差异化、生产规模和伙伴关係弹性三者共同驱动的。成熟的跨国公司利用其庞大的产品线和全球生产网络，持续支援后期研发和大规模商业化部署；而规模较小的生物技术公司则往往专注于独特的作用机制和适合许可和合作开发的平台技术。合约研发生产机构（CDMO）是生技药品和疫苗生产的策略性促进者，它们提供柔软性的生产能力和专业知识，并能缩短缺乏固定生产资产的申办者进行临床试验的时间。

行业领导者应采取切实可行的高优先级措施，以增强其整个治疗产品组合的供应韧性、证据生成和以患者为中心的市场进入。

产业领导者应采取一系列优先且切实可行的措施，以应对不断变化的科学、监管和供应链环境。首先，企业需要将供应链韧性作为核心策略目标，具体措施包括供应商多元化、寻求区域性生产方案以及正式建立紧急储备。这些措施将有助于降低贸易政策衝击带来的风险，并保障医疗服务的连续性。其次，将真实世界资料（REW）收集融入产品上市和上市后活动中，将有助于加快支付方的接受度，并支持灵活的监管路径。因此，各机构应投资于数位资料收集工具和跨相关人员的证据伙伴关係，以确保获得高品质的长期结果资料。

采用透明、多方面的研究途径，结合专家访谈、对二手证据进行三角检验和检验程序，确保研究结果的实用性和可重复性。

本分析的调查方法透过整合多源证据、与相关专家合作以及严格的检验通讯协定，确保了研究结果的稳健性和相关性。关键投入包括对临床医生、供应链高管、监管专家和销售主管进行结构化访谈，以收集有关临床实践、采购决策和生产策略的一线观点。这些质性见解与同侪审查的临床文献、公开的监管指导文件和企业资讯披露等二手资料进行交叉比对，从而建立基于事实的治疗方法特征和监管趋势标准。

透过整合强调韧性、实证市场进入和营运协调的策略挑战，我们加快部署速度并改善患者预后。

总之，感染疾病治疗正受到多种复杂因素的共同影响而重塑，这些因素包括快速的科学创新、不断变化的监管预期以及因关税调整等政策变化而加剧的供应链现状。这些趋势要求整个价值链上的相关人员——包括研发者、製造商、支付者和医疗保健系统——采取整合策略，将科学差异化与营运韧性相结合。本报告提出的细分框架揭示了治疗特性、给药途径、临床适应症和分销管道的交汇点，这些交汇点带来了独特的策略挑战。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：感染疾病治疗药物市场：依药物类别划分

  • 抗生素
    • Aminoglycosides
    • β-内酰胺
    • Fluoroquinolones
    • 大环内酯类
    • 四环霉素
  • 抗真菌药物
    • Azole
    • Echinocandins
    • Polyenes
  • 抗病毒药物
    • 整合酶抑制剂
    • 神经氨酸酶抑制剂
    • 核苷类似物
    • 蛋白酶抑制剂
  • 生物製药
    • 细胞激素
    • 单株抗体
  • 疫苗
    • 组合型
    • 失活
    • 活病毒疫苗
    • 次单元

第九章：感染疾病治疗药物市场：依给药途径划分

  • 吸入
  • 静脉
  • 口服
  • 外用

第十章：感染疾病治疗市场：依适应症划分

  • COVID-19
  • 胃肠道感染疾病
  • 肝炎
  • 爱滋病毒/爱滋病
  • 呼吸道感染疾病
  • 皮肤感染疾病
  • 尿道感染

第十一章：感染疾病治疗市场：依最终用户划分

  • 诊所
  • 居家医疗
  • 医院

第十二章：感染疾病治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：感染疾病治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：感染疾病治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：感染疾病治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国感染疾病治疗药物市场

第十七章：中国感染疾病治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Allergan PLC
  • Amgen Inc.
  • Astellas Pharma US, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioCryst Pharmaceuticals, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chimerix, Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Chemical Group Corporation
  • Mylan NV
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
Product Code: MRR-F6513A06BE17

The Infectious Disease Therapeutics Market was valued at USD 126.80 billion in 2025 and is projected to grow to USD 132.59 billion in 2026, with a CAGR of 5.39%, reaching USD 183.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 126.80 billion
Estimated Year [2026] USD 132.59 billion
Forecast Year [2032] USD 183.13 billion
CAGR (%) 5.39%

Concise strategic framing of the infectious disease therapeutics environment to orient stakeholders around clinical innovation, regulatory dynamics, and operational priorities

The infectious disease therapeutics landscape is at a pivotal inflection point driven by advances in molecular biology, accelerated vaccine development pathways, and an increasingly complex global supply environment. This introduction frames the strategic context for stakeholders across research, manufacturing, clinical practice, and policy, emphasizing the confluence of scientific innovation and regulatory adaptation that shapes near-term decisions. It establishes the analytical lens used throughout this report: an integrated view that links therapeutic modality, route of administration, and end-user realities to operational constraints and commercial opportunity.

In the following sections, the reader will encounter assessments of market dynamics, policy shocks, and segmentation-specific implications that collectively inform high-priority actions. The narrative prioritizes translational considerations: how pipeline innovations move from lab to clinic, how manufacturing resilience influences product availability, and how distribution channels modulate access at the point of care. By synthesizing technical, regulatory, and commercial vectors, this introduction prepares the reader to interpret downstream chapters with a focus on practical implications for investment, partnership, and operational planning.

How converging technological advances, regulatory modernization, and shifting clinical demand are redefining development pathways and commercialization strategies for infectious disease therapies

Transformative shifts in infectious disease therapeutics are unfolding through technological breakthroughs, novel regulatory paradigms, and shifting patterns of clinical demand. Gene-based and biologic approaches have matured to the point where monoclonal antibodies and cytokine modulators are not only therapeutic tools but also essential components of integrated treatment regimens. Concurrently, vaccine technology platforms that enable rapid design, iterative improvements, and adaptive manufacturing are reshaping prevention strategies across diverse pathogen classes. These technical developments are accompanied by digital and diagnostic advances that allow for earlier detection and more targeted therapy selection, thereby altering clinical pathways and payer considerations.

Beyond science, regulatory agencies have adopted more flexible review mechanisms and emergency-use frameworks that, while expediting access, require sponsors to engage in more continuous post-market evidence generation. As a result, commercialization strategies increasingly require lifecycle planning that balances accelerated entry with robust real-world evidence programs. In parallel, health systems are recalibrating procurement and formularies to favor products that demonstrate not only clinical efficacy but also demonstrable supply resilience and affordability. Taken together, these shifts demand that companies re-architect R&D pipelines, manufacturing footprints, and market access approaches to remain competitive and responsive to rapidly evolving clinical needs.

Comprehensive analysis of how 2025 tariff developments are recalibrating supply chain strategies, procurement decisions, and manufacturing localization across therapeutics

The cumulative effects of United States tariff policy developments in 2025 are shaping supply-chain economics, procurement behaviors, and strategic sourcing decisions across the infectious disease therapeutics ecosystem. Tariff changes have had a direct bearing on the cost of active pharmaceutical ingredients, certain biologics inputs, and reagents critical to both commercial manufacturing and research operations. The resulting pressure on unit economics has compelled manufacturers to revisit supplier diversification, inventory stocking policies, and nearshoring alternatives to mitigate exposure to import-related cost volatility.

In response, forward-looking organizations have accelerated investments in localized manufacturing capabilities and strategic partnerships with contract development and manufacturing organizations that offer regional resiliency. These moves are intended to insulate production from tariff-induced margin erosion while preserving speed-to-market for high-priority products. Additionally, procurement teams have adopted more granular cost-control measures, renegotiating long-term contracts and applying total landed cost analysis rather than price-per-unit alone. Regulatory and reimbursement stakeholders have likewise taken notice: payers are scrutinizing cost drivers more closely, and health systems are incorporating supply-chain risk assessments into formulary decisions.

Finally, the tariff environment has amplified the importance of policy engagement. Industry participants are increasingly proactive in articulating the downstream clinical and public-health implications of trade measures, aiming to inform adjustments that preserve patient access and maintain manufacturing competitiveness. Overall, the 2025 tariff context has not only reallocated cost burdens but also catalyzed structural shifts in sourcing, manufacturing strategy, and stakeholder alignment across the therapeutic value chain.

Integrated segmentation perspective connecting therapeutic class, administration route, clinical indication, distribution channel, and end-user dynamics to inform prioritization

Segmentation analysis illuminates product, administration, and clinical-use distinctions that fundamentally alter development and commercialization approaches. When viewed through drug class lenses such as antibiotics, antifungals, antivirals, biologics, and vaccines, each category presents unique clinical and manufacturing considerations. Antibiotics retain importance across diverse sub-classes including aminoglycosides, beta-lactams, fluoroquinolones, macrolides, and tetracyclines, each with differing resistance dynamics and stewardship imperatives that influence clinical guidelines and procurement preferences. Antifungal therapies, encompassing azoles, echinocandins, and polyenes, face distinct diagnostics and dosing complexities that shape hospital formulary uptake and outpatient treatment pathways. Antiviral agents such as integrase inhibitors, neuraminidase inhibitors, nucleoside analogues, and protease inhibitors exhibit therapeutic specificity and resistance profiles that drive combination strategies and adherence interventions.

Biologics, including cytokines and monoclonal antibodies, require sophisticated cold-chain logistics and manufacturing control strategies that differentiate them from small-molecule agents, while vaccine types such as conjugate, inactivated, live attenuated, and subunit platforms each demand tailored manufacturing footprints, cold-chain requirements, and regulatory dossiers. Route of administration is a pivotal segmentation axis: inhalation, intravenous, oral, and topical modalities affect patient adherence, site-of-care economics, and distribution channel suitability. Indication-specific segmentation further refines strategic choices; therapeutic focus areas such as COVID-19, gastrointestinal infections, hepatitis, HIV/AIDS, respiratory infections, skin infections, and urinary tract infections create distinct clinical trial designs, real-world evidence needs, and payer conversations. Distribution channel distinctions among hospital pharmacy, online pharmacy, and retail pharmacy shape fulfillment models and post-market surveillance pathways, while end-user segmentation - clinics, homecare, and hospitals - determines service delivery models, capacity planning, and support-service requirements.

Bringing these segmentation dimensions together enables stakeholders to identify where clinical unmet needs intersect with advantageous product characteristics, where manufacturing complexity aligns with reimbursement potential, and where route-of-administration innovations can unlock new access pathways. This integrated segmentation perspective supports more precise prioritization of portfolio investments, targeted engagement with clinical and payer stakeholders, and optimized distribution strategies that reflect distinct use-case realities.

How regional regulatory diversity, manufacturing capacity, and health-system priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific determine access and strategic focus

Regional dynamics exert a material influence on regulatory timelines, manufacturing strategy, and patient access across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, regulatory environments vary from highly centralized systems with robust approval pathways to fragmented jurisdictional landscapes that can slow cross-border access; this diversity necessitates differentiated market-entry tactics, strategic pricing discussions, and contingency plans for supply continuity. In the Europe Middle East & Africa context, stakeholders must navigate a mosaic of regulatory approaches, reimbursement frameworks, and public-health priorities, where collaborative procurement mechanisms and regional disease burden profiles play a significant role in adoption curves and public tenders.

Asia-Pacific presents a dynamic mix of established and rapidly evolving markets, with strong local manufacturing capacity in several economies and growing demand for both advanced biologics and accessible small-molecule therapies. Policy drivers in this region often prioritize self-reliance in critical medicines, fostering investment in domestic production and technology transfer. Across regions, differences in health-system funding mechanisms, public-health priorities, and logistical constraints shape where investment in cold-chain infrastructure, point-of-care diagnostics, and decentralized delivery models will yield the greatest returns. Importantly, regional regulatory harmonization efforts and multilateral procurement initiatives have the potential to lower barriers to entry for innovative therapies, provided that sponsors align dossiers and evidence-generation strategies to meet cross-jurisdictional requirements.

Key competitive patterns revealing how scientific differentiation, manufacturing strategy, and partnership models drive success in infectious disease therapeutics

Competitive dynamics among leading companies in infectious disease therapeutics are driven by a combination of scientific differentiation, manufacturing scale, and partnership agility. Established multinational firms continue to leverage deep pipelines and global manufacturing networks to support late-stage development and broad commercial launches, while smaller biotechnology companies often focus on niche mechanisms of action or platform technologies that can be licensed or co-developed. Contract development and manufacturing organizations have become strategic enablers, offering flexibility in capacity and specialized know-how for biologic and vaccine production, which accelerates time-to-clinic for sponsors without fixed manufacturing assets.

Across the landscape, successful companies deploy a mix of business models: some prioritize vertically integrated control over manufacturing to ensure supply resilience, while others pursue asset-light approaches that emphasize speed and portfolio breadth through external partnerships. Digital capabilities-ranging from advanced analytics for pharmacovigilance to remote patient monitoring and adherence platforms-are increasingly used to differentiate commercial propositions and support payer dialogues. Strategic alliances between therapeutic developers, diagnostic firms, and distribution partners are also more common, reflecting a recognition that bundled solutions can improve clinical outcomes and simplify procurement for health systems. In sum, the competitive landscape rewards organizations that combine scientific rigor with operational adaptability and collaborative go-to-market strategies.

Practical high-priority actions for industry leaders to strengthen supply resilience, evidence generation, and patient-centric market access across therapeutic portfolios

Industry leaders should adopt a set of prioritized, actionable measures to navigate evolving scientific, regulatory, and supply-chain realities. First, companies must embed supply resilience as a core strategic objective by diversifying supplier bases, pursuing regional manufacturing options, and formalizing contingency inventories; such measures reduce exposure to trade-policy shocks and maintain continuity of care. Second, integrating real-world evidence generation into launch and post-marketing activities will accelerate payer acceptance and support adaptive regulatory pathways, so organizations should invest in digital data capture tools and cross-stakeholder evidence partnerships to ensure high-quality, longitudinal outcome data.

Third, commercial strategies must increasingly account for route-of-administration and end-user preferences; developing patient-centric formulations or delivery options that enable homecare and outpatient treatment can shift utilization patterns in a way that benefits both patients and payers. Fourth, strategic partnerships with contract manufacturers, diagnostics firms, and regional distributors should be pursued proactively to manage capacity constraints and streamline market access. Finally, companies should prioritize transparent engagement with policymakers and procurement bodies to communicate clinical value and the implications of trade or tariff policies on access. Collectively, these actions balance short-term operational imperatives with long-term value creation and resilience.

Transparent multi-method research approach combining expert interviews, secondary evidence triangulation, and validation procedures to ensure actionable and reproducible insights

The research methodology underpinning this analysis combined multi-source evidence synthesis, targeted expert engagement, and rigorous validation protocols to ensure robustness and relevance. Primary inputs included structured interviews with clinicians, supply-chain executives, regulatory specialists, and commercial leaders to capture first-hand perspectives on clinical practice, procurement decision-making, and manufacturing strategy. These qualitative insights were triangulated with secondary source materials such as peer-reviewed clinical literature, publicly available regulatory guidance documents, and company disclosures to establish a factual baseline for therapeutic modality characteristics and regulatory trends.

To ensure analytical rigor, findings were cross-validated through iterative consultations with subject-matter experts and technical reviewers who assessed assumptions about clinical adoption, manufacturing complexity, and distribution logistics. Data quality controls included source provenance checks, conflict-of-interest screening for interview participants, and an audit trail documenting how primary and secondary inputs informed each analytical conclusion. The methodology emphasizes transparency and reproducibility; detailed appendices provide interview protocols, inclusion criteria for secondary sources, and definitions for segmentation axes so that readers can evaluate the basis for strategic recommendations and adapt insights to their own operational contexts.

Synthesis of strategic imperatives emphasizing resilience, evidence-driven market access, and operational alignment to accelerate adoption and improve patient outcomes

In conclusion, infectious disease therapeutics are being reshaped by intersecting forces: rapid scientific innovation, evolving regulatory expectations, and supply-chain realities intensified by policy shifts such as tariff adjustments. These dynamics demand that stakeholders across the value chain-developers, manufacturers, payers, and health systems-adopt integrated strategies that align scientific differentiation with operational resilience. The segmentation framework presented in this report clarifies where therapeutic characteristics, administration routes, clinical indications, and distribution channels converge to create distinct strategic imperatives.

Looking ahead, success will favor organizations that can translate technical innovations into scalable production and delivery models while maintaining flexible, evidence-driven approaches to market access. Proactive engagement with regulatory and procurement stakeholders, targeted investments in manufacturing and data infrastructure, and creative partnership models will be central to sustaining competitive advantage. The synthesis provided here is intended to support informed decision-making by highlighting where effort and capital can most effectively reduce risk, accelerate adoption, and ultimately improve patient outcomes across diverse infectious disease priorities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infectious Disease Therapeutics Market, by Drug Class

  • 8.1. Antibiotics
    • 8.1.1. Aminoglycosides
    • 8.1.2. Beta Lactams
    • 8.1.3. Fluoroquinolones
    • 8.1.4. Macrolides
    • 8.1.5. Tetracyclines
  • 8.2. Antifungals
    • 8.2.1. Azoles
    • 8.2.2. Echinocandins
    • 8.2.3. Polyenes
  • 8.3. Antivirals
    • 8.3.1. Integrase Inhibitors
    • 8.3.2. Neuraminidase Inhibitors
    • 8.3.3. Nucleoside Analogues
    • 8.3.4. Protease Inhibitors
  • 8.4. Biologics
    • 8.4.1. Cytokines
    • 8.4.2. Monoclonal Antibodies
  • 8.5. Vaccines
    • 8.5.1. Conjugate
    • 8.5.2. Inactivated
    • 8.5.3. Live Attenuated
    • 8.5.4. Subunit

9. Infectious Disease Therapeutics Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Topical

10. Infectious Disease Therapeutics Market, by Indication

  • 10.1. COVID-19
  • 10.2. Gastrointestinal Infections
  • 10.3. Hepatitis
  • 10.4. HIV/AIDS
  • 10.5. Respiratory Infections
  • 10.6. Skin Infections
  • 10.7. Urinary Tract Infections

11. Infectious Disease Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Homecare
  • 11.3. Hospitals

12. Infectious Disease Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Infectious Disease Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Infectious Disease Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Infectious Disease Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Infectious Disease Therapeutics Market

17. China Infectious Disease Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Alexion Pharmaceuticals, Inc.
  • 18.7. Allergan PLC
  • 18.8. Amgen Inc.
  • 18.9. Astellas Pharma US, Inc.
  • 18.10. AstraZeneca PLC
  • 18.11. Bayer AG
  • 18.12. BioCryst Pharmaceuticals, Inc.
  • 18.13. Biogen Inc.
  • 18.14. Boehringer Ingelheim GmbH
  • 18.15. Bristol-Myers Squibb Company
  • 18.16. Celgene Corporation
  • 18.17. Chimerix, Inc.
  • 18.18. Eli Lilly and Company
  • 18.19. Gilead Sciences, Inc.
  • 18.20. GlaxoSmithKline PLC
  • 18.21. Johnson & Johnson Services, Inc.
  • 18.22. Merck & Co., Inc.
  • 18.23. Mitsubishi Chemical Group Corporation
  • 18.24. Mylan N.V.
  • 18.25. Novartis AG
  • 18.26. Novo Nordisk A/S
  • 18.27. Pfizer Inc.
  • 18.28. Sanofi S.A.
  • 18.29. Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 236. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 240. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 268. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 269. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 270. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 271. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 272. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 273. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 280. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 282. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 283. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 284. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 286. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. U